Intranasal administration of a flagellin-adjuvanted inactivated influenza vaccine enhances mucosal immune responses to protect mice against lethal infection

Vaccine

Volumn 30, Issue 2, 2012, Pages 466-474

  Hong, Seol Hee ^a   Byun, Young Ho ^b   Nguyen, Chung Truong ^a   Kim, Soo Young ^a   Seong, Baik Lin ^b   Park, Songyong ^c   Woo, Gyu Jin ^c   Yoon, Yeup ^c   Koh, Jeong Tae ^a   Fujihashi, Kohtaro ^d   Rhee, Joon Haeng ^a   Lee, Shee Eun ^a  

^a Chonnam National University   (South Korea)

^b Yonsei University   (South Korea)

^c Mogam Biotechnology Research Institute   (South Korea)

^d UNIVERSITY OF ALABAMA AT BIRMINGHAM   (United States)

Author keywords

Adjuvant; Flagellin; IgA; Inactivated influenza vaccine; Intranasal; Protective immunity

Indexed keywords

FLAGELLIN; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INACTIVATED VIRUS VACCINE; INFLUENZA VACCINE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN SPECIFICITY; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; HUMORAL IMMUNITY; IMMUNE RESPONSE; INFLUENZA; INFLUENZA VIRUS A H1N1; INFLUENZA VIRUS A H3N2; INFLUENZA VIRUS B; LYMPH NODE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; VACCINATION; VIBRIO VULNIFICUS;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ANIMALS; ANTIBODIES, VIRAL; DISEASE MODELS, ANIMAL; FEMALE; FLAGELLIN; IMMUNITY, MUCOSAL; IMMUNOGLOBULIN A; IMMUNOGLOBULIN G; INFLUENZA VACCINES; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; RESPIRATORY MUCOSA; SURVIVAL ANALYSIS; VACCINES, INACTIVATED;

EID: 84355161545     PISSN: 0264410X     EISSN: 18732518     Source Type: Journal    
DOI: 10.1016/j.vaccine.2011.10.058     Document Type: Article

References (53)

1. Lambert L.C., Fauci A.S. Influenza vaccines for the future. N Engl J Med 2010, 363(21):2036-2044.
2. Girard M.P., Cherian T., Pervikov Y., Kieny M.P. A review of vaccine research and development: human acute respiratory infections. Vaccine 2005, 23(50):5708-5724.
3. Thompson W.W., Comanor L., Shay D.K. Epidemiology of seasonal influenza: use of surveillance data and statistical models to estimate the burden of disease. J Infect Dis 2006, 194(Suppl 2):S82-S91.
4. Thompson W.W., Moore M.R., Weintraub E., Cheng P.Y., Jin X., Bridges C.B., et al. Estimating influenza-associated deaths in the United States. Am J Public Health 2009, 99(October (Suppl 2)):S225-S230.
5. Cox N.J., Subbarao K. Influenza. Lancet 1999, 354(9186):1277-1282.
6. Holmgren J., Czerkinsky C. Mucosal immunity and vaccines. Nat Med 2005, 11(April (4 Suppl)):S45-S53.
7. Chen K., Cerutti A. Vaccination strategies to promote mucosal antibody responses. Immunity 2010, 33(4):479-491.
8. Park K.S., Lee J., Ahn S.S., Byun Y.H., Seong B.L., Baek Y.H., et al. Mucosal immunity induced by adenovirus-based H5N1 HPAI vaccine confers protection against a lethal H5N2 avian influenza virus challenge. Virology 2009, 395(2):182-189.
9. Skountzou I., Martin Mdel P., Wang B., Ye L., Koutsonanos D., Weldon W., et al. Salmonella flagellins are potent adjuvants for intranasally administered whole inactivated influenza vaccine. Vaccine 2010, 28(24):4103-4112.
10. Lee Y.S., Lee K.A., Lee J.Y., Kang M.H., Song Y.C., Baek D.J., et al. An alpha-GalCer analogue with branched acyl chain enhances protective immune responses in a nasal influenza vaccine. Vaccine 2011, 29(3):417-425.
11. Masic A., Lu X., Li J., Mutwiri G.K., Babiuk L.A., Brown E.G., et al. Immunogenicity and protective efficacy of an elastase-dependent live attenuated swine influenza virus vaccine administered intranasally in pigs. Vaccine 2010, 28(43):7098-7108.
12. Youn H.J., Ko S.Y., Lee K.A., Ko H.J., Lee Y.S., Fujihashi K., et al. A single intranasal immunization with inactivated influenza virus and alpha-galactosylceramide induces long-term protective immunity without redirecting antigen to the central nervous system. Vaccine 2007, 25(28):5189-5198.
13. Ichinohe T., Ainai A., Tashiro M., Sata T., Hasegawa H. PolyI:polyC12U adjuvant-combined intranasal vaccine protects mice against highly pathogenic H5N1 influenza virus variants. Vaccine 2009, 27(45):6276-6279.
14. Belshe R.B., Nichol K.L., Black S.B., Shinefield H., Cordova J., Walker R., et al. Safety, efficacy, and effectiveness of live, attenuated, cold-adapted influenza vaccine in an indicated population aged 5-49 years. Clin Infect Dis 2004, 39(7):920-927.
15. Mendelman P.M., Rappaport R., Cho I., Block S., Gruber W., August M., et al. Live attenuated influenza vaccine induces cross-reactive antibody responses in children against an a/Fujian/411/2002-like H3N2 antigenic variant strain. Pediatr Infect Dis J 2004, 23(November (11)):1053-1055.
16. Monto A.S., Comanor L., Shay D.K., Thompson W.W. Epidemiology of pandemic influenza: use of surveillance and modeling for pandemic preparedness. J Infect Dis 2006, 194(Suppl 2):S92-S97.
17. Thompson W.W., Shay D.K., Weintraub E., Brammer L., Cox N.J., Fukuda K. Influenza vaccination among the elderly in the United States. Arch Intern Med 2005, 165(17):2038-2039. [author reply 9-40].
18. Couch R.B., Winokur P., Brady R., Belshe R., Chen W.H., Cate T.R., et al. Safety and immunogenicity of a high dosage trivalent influenza vaccine among elderly subjects. Vaccine 2007, 25(44):7656-7663.
19. Lawson L.B., Norton E.B., Clements J.D. Defending the mucosa: adjuvant and carrier formulations for mucosal immunity. Curr Opin Immunol 2011, 23(3):414-420.
20. Norton E.B., Lawson L.B., Freytag L.C., Clements J.D. Characterization of a mutant Escherichia coli heat-labile toxin, LT(R192G/L211A), as a safe and effective oral adjuvant. Clin Vaccine Immunol 2011, 18(April (4)):546-551.
21. Vajdy M, editor. Immunity against mucosal pathogens; 2010.
22. Freytag L.C., Clements J.D. Mucosal adjuvants. Vaccine 2005, 23(15):1804-1813.
23. Mutsch M., Zhou W., Rhodes P., Bopp M., Chen R.T., Linder T., et al. Use of the inactivated intranasal influenza vaccine and the risk of Bell's palsy in Switzerland. N Engl J Med 2004, 350(9):896-903.
24. van Ginkel F.W., Jackson R.J., Yoshino N., Hagiwara Y., Metzger D.J., Connell T.D., et al. Enterotoxin-based mucosal adjuvants alter antigen trafficking and induce inflammatory responses in the nasal tract. Infect Immun 2005, 73(October (10)):6892-6902.
25. Akira S., Uematsu S., Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124(4):783-801.
26. Medzhitov R. Recognition of microorganisms and activation of the immune response. Nature 2007, 449(7164):819-826.
27. Steinhagen F., Kinjo T., Bode C., Klinman D.M. TLR-based immune adjuvants. Vaccine 2011, 29(17):3341-3355.
28. Schwarz T.F. Clinical update of the AS04-adjuvanted human papillomavirus-16/18 cervical cancer vaccine, Cervarix. Adv Ther 2009, 26(November (11)):983-998.
29. Brandtzaeg P. Role of secretory antibodies in the defence against infections. Int J Med Microbiol 2003, 293(April (1)):3-15.
30. Tumpey T.M., Renshaw M., Clements J.D., Katz J.M. Mucosal delivery of inactivated influenza vaccine induces B-cell-dependent heterosubtypic cross-protection against lethal influenza A H5N1 virus infection. J Virol 2001, 75(June (11)):5141-5150.
31. Asahi Y., Yoshikawa T., Watanabe I., Iwasaki T., Hasegawa H., Sato Y., et al. Protection against influenza virus infection in polymeric Ig receptor knockout mice immunized intranasally with adjuvant-combined vaccines. J Immunol 2002, 168(6):2930-2938.
32. Lee M.S., Yang C.F. Cross-reactive H1N1 antibody responses to a live attenuated influenza vaccine in children: implication for selection of vaccine strains. J Infect Dis 2003, 188(9):1362-1366.
33. Brandtzaeg P. Role of mucosal immunity in influenza. Dev Biol (Basel) 2003, 115:39-48.
34. Clements M.L., Murphy B.R. Development and persistence of local and systemic antibody responses in adults given live attenuated or inactivated influenza A virus vaccine. J Clin Microbiol 1986, 23(January (1)):66-72.
35. Lee S.E., Kim S.Y., Jeong B.C., Kim Y.R., Bae S.J., Ahn O.S., et al. A bacterial flagellin, Vibrio vulnificus FlaB, has a strong mucosal adjuvant activity to induce protective immunity. Infect Immun 2006, 74(January (1)):694-702.
36. Lee S.E., Koh Y.I., Kim M.K., Kim Y.R., Kim S.Y., Nam J.H., et al. Inhibition of airway allergic disease by co-administration of flagellin with allergen. J Clin Immunol 2008, 28(March (2)):157-165.
37. McBrayer A., Camp J.V., Tapp R., Yamshchikov V., Grimes S., Noah D.L., et al. Course of seasonal influenza A/Brisbane/59/07 H1N1 infection in the ferret. Virol J 2010, 7:149.
38. Camilloni B., Neri M., Lepri E., Basileo M., Sigismondi N., Puzelli S., et al. An influenza B outbreak during the 2007/2008 winter among appropriately immunized elderly people living in a nursing home. Vaccine 2010, 28(47):7536-7541.
39. Nakowitsch S., Wolschek M., Morokutti A., Ruthsatz T., Krenn B.M., Ferko B., et al. Mutations affecting the stability of the haemagglutinin molecule impair the immunogenicity of live attenuated H3N2 intranasal influenza vaccine candidates lacking NS1. Vaccine 2011, 29(19):3517-3524.
40. Song J.H., Nguyen H.H., Cuburu N., Horimoto T., Ko S.Y., Park S.H., et al. Sublingual vaccination with influenza virus protects mice against lethal viral infection. Proc Natl Acad Sci U S A 2008, 105(5):1644-1649.
41. Perron H., Garson J.A., Bedin F., Beseme F., Paranhos-Baccala G., Komurian-Pradel F., et al. Molecular identification of a novel retrovirus repeatedly isolated from patients with multiple sclerosis. The Collaborative Research Group on Multiple Sclerosis. Proc Natl Acad Sci U S A 1997, 94(14):7583-7588.
42. Seo S.U., Kwon H.J., Ko H.J., Byun Y.H., Seong B.L., Uematsu S., et al. Type I interferon signaling regulates Ly6C(hi) monocytes and neutrophils during acute viral pneumonia in mice. PLoS Pathog 2011, 7(February (2)):e1001304.
43. Yoshino N., Fujihashi K., Hagiwara Y., Kanno H., Takahashi K., Kobayashi R., et al. Co-administration of cholera toxin and apple polyphenol extract as a novel and safe mucosal adjuvant strategy. Vaccine 2009, 27(35):4808-4817.
44. Nguyen C.T., Kim S.Y., Kim M.S., Lee S.E., Rhee J.H. Intranasal immunization with recombinant PspA fused with a flagellin enhances cross-protective immunity against Streptococcus pneumoniae infection in mice. Vaccine 2011, 29(34):5731-5739.
45. de Jong J.C., Palache A.M., Beyer W.E., Rimmelzwaan G.F., Boon A.C., Osterhaus A.D. Haemagglutination-inhibiting antibody to influenza virus. Dev Biol (Basel) 2003, 115:63-73.
46. Belshe R., Lee M.S., Walker R.E., Stoddard J., Mendelman P.M. Safety, immunogenicity and efficacy of intranasal, live attenuated influenza vaccine. Expert Rev Vaccines 2004, 3(December (6)):643-654.
47. Cox R.J., Brokstad K.A., Ogra P. Influenza virus: immunity and vaccination strategies. Comparison of the immune response to inactivated and live, attenuated influenza vaccines. Scand J Immunol 2004, 59(January (1)):1-15.
48. Verdijk P., Rots N.Y., Bakker W.A. Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains. Expert Rev Vaccines 2011, 10(May (5)):635-644.
49. Renegar K.B., Small P.A., Boykins L.G., Wright P.F. Role of IgA versus IgG in the control of influenza viral infection in the murine respiratory tract. J Immunol 2004, 173(3):1978-1986.
50. Bizanov G., Janakova L., Knapstad S.E., Karlstad T., Bakke H., Haugen I.L., et al. Immunoglobulin-A antibodies in upper airway secretions may inhibit intranasal influenza virus replication in mice but not protect against clinical illness. Scand J Immunol 2005, 61(June (6)):503-510.
51. Brandtzaeg P., Johansen F.E. Mucosal B cells: phenotypic characteristics, transcriptional regulation, and homing properties. Immunol Rev 2005, 206(August):32-63.
52. Johansen F.E., Baekkevold E.S., Carlsen H.S., Farstad I.N., Soler D., Brandtzaeg P. Regional induction of adhesion molecules and chemokine receptors explains disparate homing of human B cells to systemic and mucosal effector sites: dispersion from tonsils. Blood 2005, 106(2):593-600.
53. Devito C., Zuber B., Schroder U., Benthin R., Okuda K., Broliden K., et al. Intranasal HIV-1-gp160-DNA/gp41 peptide prime-boost immunization regimen in mice results in long-term HIV-1 neutralizing humoral mucosal and systemic immunity. J Immunol 2004, 173(11):7078-7089.